KMTS at a glance
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS, SEC CIK 1877184) filed its latest 10-K annual report on July 14, 2026, a 10-Q quarterly report on September 14, 2026, an 8-K current report on September 14, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended April 30, 2026 (FY2026), KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported revenue of $95.1 million (up 59.0% from FY2025) and a net loss of $131.6 million. Diluted EPS was -$2.43.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) shares worth $424.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by COHEN RAYMOND W on September 30, 2026 of 3,330 shares at $29.28 per share.
- In the last 90 days, KMTS insiders reported 0 open-market purchases ($0) and 34 open-market sales ($6.3M) on Form 4, a net sale of $6.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $95.1M
- +59.0% vs prior year
- Insiders · 90 days
- 0 buys · 34 sells
- Net −$6.3M
- 13F holders
- 22 funds
- $424.9M · +3 vs prior quarter
- Latest 8-K
- Sep 14, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Apr 30, 2026
Business Overview
- Core business model: commercial-stage wearable medical device and digital healthcare company focused on cardiovascular patient monitoring and therapy via the Cardiac Recovery System platform anchored by the ASSURE WCD
- New product emphasis: April 2026 launch of Enhanced ASSURE Detection Algorithm improving rhythm discrimination and reducing false alarms to estimated 3% from prior 6%
- Strategic shift: plans to expand internationally with CE Mark pursuit targeting Western Europe within three years, marking first regulatory approval efforts outside the U.S.
- Quantitative metric: commercial protection of nearly 40,000 patients by April 2026 and enrollment of ~40,000 patients in ongoing ASSURE Patient Registry
- Noteworthy fact: strategic collaboration in January 2026 with Biobeat Technologies to integrate FDA-cleared cuffless ambulatory blood pressure monitoring into product portfolio
Risk Factors
- Regulatory risk: Ongoing enforcement and compliance scrutiny by DOJ, HHS OIG, state attorneys general, and CMS around financial relationships with healthcare providers and billing practices
- Macroeconomic threat: Inflation and inflation-driven cost increases for materials, labor, shipping, and component shortages may raise manufacturing expenses and reduce profitability
- Operational vulnerability: Reliance on limited suppliers for ASSURE WCD components, with no large inventory; delays in component supply or device reconditioning by third-party manufacturers risk product shortages
- Competitive risk: Primary competitor ZOLL Medical (Asahi Kasei subsidiary) and a new FDA-approved adhesive-based external defibrillator competitor threaten market share
- Financial risk: $45 million Term Loan with collateral on all assets and restrictive covenants limits operational flexibility and requires substantial quarterly interest payments
Management Discussion & Analysis
- Revenue $95.1M, up 59% YoY from $59.8M in 2025, driven by 58% patient growth
- Gross profit $48.9M (51.4% margin) vs $24.2M (40.5% margin) in 2025; gross profit margin increased ~11pp
- Best segment: Leasing of ASSURE WCD with revenue $95.1M; no separate segments disclosed
- Operating loss widened to $134.7M from $106.4M; R&D increased 24% to $19.5M, SG&A up 43% to $164.1M
- Cash flow: Operating cash outflow $81.7M; investing cash outflow $203.3M; financing cash inflow $147.1M including $149.3M secondary offering
- Capital allocation: Raised $149.3M in Dec 2025 offering; invested $34.9M in property/equipment; no buybacks/dividends reported
- Outlook: Existing cash $262.2M sufficient for 12+ months; risk of needing future funding if costs rise or cash from operations lags
AI summary of the KMTS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 31, 2026
Risk Factors
- New 2026 Term Loan refinancing risk triggered by July 10 financing, including senior secured debt maturing July 10, 2031
- Liquidity risk with $244.7 million cash and investments against $32.3 million quarterly negative operating cash flow
- Reimbursement risk from Medicare, Medicaid, and private-payor coverage and collection requirements
- Operational risk from outsourced manufacturing of ASSURE® WCD components
- Competitive risk from continued investment needed to recruit, train, and retain the direct sales force
AI summary of the KMTS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended July 31, 2026 results announced September 14, 2026
- Financial details furnished in Exhibit 99.1, requiring review for revenue, earnings, and guidance impacts
Item EX-99.1: Item EX-99.1
- F1Q27 revenue $31.0M, up 60% year over year, driven by WCD market expansion, share gains, and improved payer mix
- Gross margin expanded to 56.5% from 45.7%, signaling meaningful volume leverage and cost-improvement benefits
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholder turnout 94.53%, with 55,399,491 of 58,603,121 outstanding shares voting
- Raymond W. Cohen, Kevin Reilly, and Traci S. Umberger elected as Class II directors through 2029
Item 1.01: Entry into a Material Definitive Agreement
- $200M five-year senior secured term facility, providing Kestra with substantial growth and acquisition financing capacity
- $75M Tranche A funded July 10, 2026; approximately $20M net proceeds after costs and repayment of prior debt
Item 1.02: Termination of a Material Definitive Agreement
- Prior Loan Agreement with Perceptive Credit Holdings IV terminated upon July 10, 2026 Loan Agreement
- Borrower’s payment and other obligations fully paid and discharged
Item 2.02: Results of Operations and Financial Condition
- Fiscal-quarter results covered period ended April 30, 2026
- Press release issued July 14, 2026
Item EX-99.1: Item EX-99.1
- FY26 revenue $95.1M, up 59%, with ASSURE prescriptions up 57% to 20,720
- Gross margin expanded to 51.4% from 40.5%, signaling improving unit economics and reimbursement mix
AI summaries of KMTS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KMTS
Don't miss the next KMTS filing
- Alerts as it files. A push when KMTS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KMTS, by share count.
- Ask anything. An AI agent that reads every KMTS filing and answers with sources.
KMTS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| COHEN RAYMOND W | Sell | Sep 30, 2026 | 3,330 | $29.28 |
| Kwo Elizabeth | Sell | Sep 21, 2026 | 4,010 | $24.26 |
| Ladone Mary Kay | A | Sep 9, 2026 | 7,217 | - |
| Hanley Conor | A | Sep 9, 2026 | 7,217 | - |
| COHEN RAYMOND W | A | Sep 9, 2026 | 7,217 | - |
| Kwo Elizabeth | A | Sep 9, 2026 | 7,217 | - |
| Schwartz Jeffrey Lawrence | A | Sep 9, 2026 | 7,217 | - |
| Reilly Kevin C | A | Sep 9, 2026 | 7,217 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $59.8M | $95.1M |
| Gross Profit | - | $24.2M | $48.9M |
| Operating Income | - | -$106.4M | -$134.7M |
| Net Income | - | -$113.8M | -$131.6M |
| Gross Margin | - | 40.5% | 51.4% |
| Op. Margin | - | -177.8% | -141.6% |
| Net Margin | - | -190.3% | -138.4% |
| Balance Sheet | |||
| Total Assets | $45.9M | $295.7M | $358.5M |
| Equity | - | $205.4M | $259.7M |
| ROE | - | -55.4% | -50.7% |
| Per Share | |||
| EPS | $-5.07 | $-5.13 | $-2.43 |
| Cash Flow | |||
| Operating CF | - | -$77.6M | -$81.7M |
| CapEx | - | $22.9M | $34.9M |
Source: XBRL data in KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate KMTS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $424.9M |
| Q1 2026 | 19 | $353.9M |
| Q4 2025 | 20 | $373.9M |
| Q3 2025 | 16 | $234.5M |
| Q2 2025 | 19 | $146.3M |
| Q1 2025 | 10 | $129.0M |
- BlackRock+176.2K (+10%)
- State Street Corp+76.6K (+11%)
- Vanguard Portfolio Management LLC+36.5K (+17%)
- Citadel Advisors LLC+21.6K (+155%)
- Northern Trust+16.6K (+9%)
- T. Rowe Price Group−999.8K (-17%)
- FMR LLC (Fidelity)−197.4K (-3%)
- Franklin Resources−119.6K (-10%)
- Morgan Stanley−92.1K (-63%)
- Vanguard Capital Management LLC−37.2K (-3%)
- AQR Capital Management+32.4K
- Allstate+25.4K
- PNC Financial Services+71
Source: 13F-HR filings on SEC EDGAR (aggregated from 106 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KMTS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 10-Q | Sep 14, 2026 | Jul 31, 2026 | Analysis | |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
KMTS SEC filings: frequently asked questions
Are KMTS insiders buying or selling?
In the last 90 days, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) officers, directors and 10% owners reported no open-market purchases and 34 open-market sales worth $6.3 million by 11 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KMTS stock?
As of June 30, 2026, the largest KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($140.5 million), T. Rowe Price Group ($126.4 million), BlackRock ($47.5 million), Vanguard Capital Management LLC ($29.9 million), Franklin Resources ($28.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KMTS's revenue in fiscal year 2026?
For the fiscal year ended April 30, 2026 (FY2026), KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported revenue of $95.1 million (up 59.0% from FY2025) and a net loss of $131.6 million. Diluted EPS was -$2.43. The figures come from the XBRL data in the 10-K.
What are the main risks in KMTS's latest 10-K?
In the 10-K filed July 14, 2026, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) flagged: Regulatory risk: Ongoing enforcement and compliance scrutiny by DOJ, HHS OIG, state attorneys general, and CMS around financial relationships with healthcare providers and billing practices. Macroeconomic threat: Inflation and inflation-driven cost increases for materials, labor, shipping, and component shortages may raise manufacturing expenses and reduce profitability. (AI summary of the Risk Factors section.)
What did KMTS report in its latest 8-K?
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an 8-K on September 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended July 31, 2026 results announced September 14, 2026.
What are the latest KMTS SEC filings?
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed its latest 10-K annual report on July 14, 2026, a 10-Q quarterly report on September 14, 2026, an 8-K current report on September 14, 2026 and a Form 4 insider filing on October 1, 2026.
What is KMTS's SEC CIK number?
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)'s SEC Central Index Key (CIK) is 1877184. EDGAR lists every KMTS filing under that number.
Ask anything about KMTS
The research agent reads KMTS's filings, financials, insider trades and 13F holders, then answers with sources.